Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-27

Clinical Trial Update: Aleniglipron Phase 2 in Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for aleniglipron in obesity-related type 2 diabetes mellitus is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aleniglipron (GSBR-1290)

Snippet

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Conditions: Obese, Obesity | Phase 2 | Status: ACTIVE_NOT_RECRUITING